KTS002

KTS002 is a preclinical oncology agent described as a “zip-code drug conjugate” (ZDC) designated ZC-DM4, developed to deliver the cytotoxic maytansinoid payload DM4 to tumor cells with high molecular precision. In preclinical multiple myeloma models, KTS002 demonstrated approximately 1000​-fold greater cytotoxicity than the anti​-BCMA antibody​–drug conjugate belantamab in p53​-deleted or p53​-mutant cells and produced dose​-dependent tumor suppression, with high doses outperforming bortezomib, while exhibiting minimal systemic toxicity in tested models.[1][9][11] The drug is being advanced by Kodikaz with a focus on high​-risk multiple myeloma, including patients harboring adverse genetic features, and is currently in IND​-enabling development.